Suppr超能文献

临床隐匿性乳腺癌的分期与治疗

Staging and treatment of clinically occult breast cancer.

作者信息

Schwartz G F, Feig S A, Rosenberg A L, Patchefsky A S, Schwartz A B

出版信息

Cancer. 1984 Mar 15;53(6):1379-84. doi: 10.1002/1097-0142(19840315)53:6<1379::aid-cncr2820530627>3.0.co;2-r.

Abstract

Five hundred fifty-seven biopsies were performed for clinically occult mammary lesions, detected by mammography as clustered calcifications or nonpalpable masses within the breast. One hundred seventy-five cancers were demonstrated within this group, including 106 invasive carcinomas, 10 microinvasive carcinomas, 45 in situ ductal carcinomas, and 14 lobular carcinomas in situ (lobular neoplasia). No patient with in situ or microinvasive carcinoma had evidence of axillary node metastases in 33 specimens studied. However, a disturbingly high proportion of those patients with invasive carcinomas, approximately 35%, had histologically confirmed axillary node metastases, despite the small size of the primary tumors. These observations suggest that the use of the term "minimal" cancer is misleading when applied to invasive carcinoma. Staging systems for breast cancer have been imprecise when referring to nonpalpable lesions. Cancers detected as clustered calcifications only or as areas of parenchymal distortion without an accompanying mass are properly considered as T-0 cancers, with a suggested T-0(m) to indicate that the lesion was detected by mammography. However, when the mammogram indicates the presence of a mass that proves to be malignant, although the clinical examination may have been negative, the cancer should be staged according to the size of the mass on the mammogram, with the notation that it was detected by mammography, e.g., T-1(m), T-2(m), etc. The incidence of axillary node metastases even in these so-called occult cancers is significant, so that recommendations for treatment for any invasive cancer, regardless of its size, must take these observations into account. Similarly, the incidence of multifocal sites of cancer within the breast, even in the noninvasive cancers encountered, must be remembered when treatment is suggested.

摘要

对557例乳腺隐匿性病变进行了活检,这些病变通过乳腺钼靶检查发现为乳腺内的簇状钙化或不可触及的肿块。该组中发现了175例癌症,包括106例浸润性癌、10例微浸润性癌、45例导管原位癌和14例小叶原位癌(小叶肿瘤)。在研究的33个标本中,原位癌或微浸润癌患者均无腋窝淋巴结转移的证据。然而,令人不安的是,尽管原发肿瘤体积较小,但那些浸润性癌患者中约35%经组织学证实有腋窝淋巴结转移。这些观察结果表明,将“微小”癌这一术语应用于浸润性癌时具有误导性。在提及不可触及的病变时,乳腺癌的分期系统并不精确。仅检测为簇状钙化或仅为实质扭曲区域而无伴随肿块的癌症应被视为T-0癌,建议用T-0(m)表示该病变是通过乳腺钼靶检查发现的。然而,当乳腺钼靶显示存在经证实为恶性的肿块时,尽管临床检查可能为阴性,该癌症应根据乳腺钼靶上肿块的大小进行分期,并注明是通过乳腺钼靶检查发现的,例如T-1(m)、T-2(m)等。即使在这些所谓的隐匿性癌症中,腋窝淋巴结转移的发生率也很高,因此对于任何浸润性癌,无论其大小,治疗建议都必须考虑到这些观察结果。同样,在建议治疗时,必须记住即使在遇到的非浸润性癌症中,乳腺内多灶性癌的发生率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验